ISTH guidelines for antithrombotic treatment in COVID‐19

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, I...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis Jg. 20; H. 10; S. 2214 - 2225
Hauptverfasser:	Schulman, Sam, Sholzberg, Michelle, Spyropoulos, Alex C., Zarychanski, Ryan, Resnick, Helaine E., Bradbury, Charlotte A., Connors, Jean Marie, Falanga, Anna, Iba, Toshiaki, Kaatz, Scott, Levy, Jerrold H., Middeldorp, Saskia, Minichiello, Tracy, Ramacciotti, Eduardo, Samama, Charles Marc, Thachil, Jecko, Broxmeyer, Lisa, International Society on Thrombosis and Haemostasis
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Inc 01.10.2022 Elsevier Limited John Wiley and Sons Inc
Schlagworte:	Aftercare anticoagulants Anticoagulants - adverse effects Coronaviruses COVID-19 critical illness Dosage Fibrinolytic Agents - adverse effects Heparin Heparin - adverse effects Heparin, Low-Molecular-Weight Hospitalization Humans Molecular weight Patient Discharge Patients platelet aggregation inhibitors Platelet Aggregation Inhibitors - adverse effects Recommendations and Guidelines Rivaroxaban Thromboembolism anticoagulants COVID‐19 critical illness platelet aggregation inhibitors COVID-19
ISSN:	1538-7836, 1538-7933, 1538-7836
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!